FANCA S1088F

CI-VAR-00003975Explore in graph →NP_000126.2:p.Ser1088PheNM_000135.2:c.3263C>TClinVar 134264 CIViC 2165 rs17233497

Curated evidence

Evidence by cancer (1 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–1 of 1 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Prostate Neoplasm1
FANCA S1088F	Cisplatin	Predictive	C	Supports Sensitivity Response	4	submitted	EID5813 A patient with prostate cancer with exceptional response to treatment was identified who harbored a somatic hemizygous deletion of the DNA repair gene FANCA and putative partial loss of function of th… (full text at CIViC) PMID 26181256 · Beltran et al., 2015 · Open in CIViC	civic

ClinVar

Clinical significance (1)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

clinvarCurated1 interpretation · review status and star rating as assigned by ClinVar.

Variation	Clinical significance	Review status	Stars	Conditions	Origin	Submitters	Last evaluated	Source
134264	Benign/Likely benign	criteria provided, multiple submitters, no conflicts	2	Fanconi anemia; Prostate cancer; Fanconi anemia complementation group A	germline	17	Feb 04, 2026	clinvar